These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Lipella Pharmaceuticals (LIPO), 7,503% surge in interest
- Eton Pharmaceuticals (ETON), 1,615% surge in interest
- Eyepoint Pharmaceuticals (EYPT), 726% surge in interest
- Minerva Neuroscience (NERV), 267% surge in interest
- Kazia Therapeutics (KZIA), 233% surge in interest
Pipeline and key clinical candidates for these companies:
Lipella is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company says it maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists, "believing that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval."
Eton Pharmaceuticals is focused on developing, acquiring, and commercializing treatments for rare diseases. The company currently commercializes ALKINDI SPRINKLE and Carglumic Acid tablets and has four additional rare disease products under development, including dehydrated alcohol injection and the ZENEO hydrocortisone autoinjector.
EyePoint Pharmaceuticals is committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company’s pipeline leverages its proprietary Durasert technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal treatment currently in Phase 2 clinical trials. The proven Durasert drug delivery platform has been "safely administered to thousands of patients’ eyes" across four U.S. FDA approved products, including Yutiq for the treatment of posterior segment uveitis, EyePoint says.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system, or CNS, diseases. Minerva’s portfolio of compounds includes roluperidone, or MIN-101, in clinical development for negative symptoms of schizophrenia, and MIN-301 for Parkinson’s disease.
Kazia Therapeutics is an oncology-focused drug development company whose lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.
Recent news on these stocks:
January 11
Lipella Pharmaceuticals announced top line results of the company’s recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments. Jonathan Kaufman, CEO, will present a corporate overview including the top-line results, at Biotech Showcase 2023 on Wednesday, January 11th at 2:00pm PST at the Hilton San Francisco. "The successful completion of the Phase 2a clinical trial of LP-10 is a critical milestone in Lipella’s development," said Kaufman. "We’re gratified with the results and look forward to our next step, which will be to communicate with the FDA on the study’s results and the pathway forward to seeking regulatory approval for LP-10. The achievement of this milestone brings Lipella one step closer to providing a first-in class treatment for the cancer survivor community with hemorrhagic cystitis." The LP-10 Phase 2a clinical trial was a multi-center, dose-escalation study. The study recruited 13 subjects with moderate to severe refractory hemorrhagic cystitis. These subjects were treated with up to two courses of LP-10 intravesical bladder instillations. All subjects tolerated LP-10 instillations and completed the study without report of product related serious adverse events. LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake. A dose response was noted and there were decreased hematuria; decreased cystoscopic bleeding and ulceration sites; and improved patients’ urinary symptoms.
Eton Pharmaceuticals announced that the FDA has accepted for review the company’s New Drug Application response for dehydrated alcohol injection for the proposed indication of methanol poisoning. The FDA has assigned a Prescription Drug User Fee Act target action date of June 27, 2023. Eton’s application has previously been granted orphan drug designation for the indication of methanol poisoning and if approved, the company expects the FDA to grant the application seven years of orphan drug exclusivity. Based on IQVIA data, trailing twelve month sales for dehydrated alcohol injection were $74M.
Trading in Kazia Therapeutics stock was halted, news pending.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KZIA:
